Isis buys drug funding entity
From Times Wire Services
Isis Pharmaceuticals Inc. has acquired all outstanding shares of Symphony GenIsis for $120 million in cash and stock.
Isis also reacquired full ownership of its cholesterol-lowering drug Isis 301012, the Carlsbad, Calif., company said.
Symphony GenIsis was formed in April 2006 by Symphony Capital Partners to fund development of three Isis drugs.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
